Jingze Biomedical

Jingze Biomedical is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development and commercialization of high-quality biosimilars and innovative biologics. The company focuses on three primary therapeutic areas: ophthalmology, reproductive health, and oncology. Its advanced pipeline includes several late-stage candidates, such as biosimilars for aflibercept and ranibizumab for retinal diseases, as well as recombinant human follicle-stimulating hormones for infertility treatments. Jingze operates a comprehensive R&D and GMP-compliant manufacturing infrastructure to support its goal of providing affordable, high-efficacy biological therapies. The company has successfully raised multiple rounds of financing from prominent investors like Sequoia China and SDIC Fund Management.